Biopharmaceutical company developing psychedelics-inspired medicines and therapies to address addiction and brain health disorders MindMed Inc. (NASDAQ: MNMD) (NEO: MMED) announced that its collaborators at University Hospital Basel; Dr. Frederike Holze and Prof. Dr. Matthias Liechti will be presenting results from an LSD-assist study phase 2 investigator-initiated clinical study of LSD in the treatment of anxiety disorders.
The company made this announcement last week further revealing their collaborators will be presenting the results at an upcoming PSYCH Symposium in London slated for May 11, 2022.
The presentation is titled ‘LSD as a Treatment for Anxiety Disorders: New Evidence of Efficacy’ and it covers preliminary topline safety and efficacy results results for lysergic acid diethylamide (LSD) across 46 patients with clinically significant anxiety.
The clinical trial was conducted at two centers including; UHB and at the private psychiatry practice of Dr. Peter Gasser. The company’s CEO, Robert Barrow, said MindMed supports the UHB Liechti Lab in conducting investigator-initiated trials for LSD and other novel therapies and has exclusive access and rights to the data generated by these studies.
“Since the 1940s, LSD has been extensively investigated for its effects in humans, showing particular benefit in mitigating symptoms of anxiety and depression. The results from this study, if positive, would further validate our approach to develop MM-120 in the treatment of Generalized Anxiety Disorder and would support the progression of our MM-120 development program. We are proud to support Dr. Liechti and his team and to extend their findings through our commercial drug development programs,” added the CEO.
